Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2

Background & Aims Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH‐2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha‐fetoprotein (AFP) ≥400 ng/mL showed an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Liver international 2020-08, Vol.40 (8), p.2008-2020
Hauptverfasser:	Kudo, Masatoshi, Galle, Peter R., Llovet, Josep M., Finn, Richard S., Vogel, Arndt, Motomura, Kenta, Assenat, Eric, Merle, Philippe, Brandi, Giovanni, Daniele, Bruno, Okusaka, Takuji, Tomášek, Jiří, Borg, Christophe, Dadduzio, Vincenzo, Morimoto, Manabu, Pracht, Marc, Jen, Min‐Hua, Drove Ubreva, Nora, Widau, Ryan C., Shinozaki, Kenta, Yoshikawa, Reigetsu, Zhu, Andrew X.
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Aged alpha-Fetoproteins alpha‐fetoprotein (AFP) Antibodies, Monoclonal, Humanized Cancer Carcinoma, Hepatocellular - drug therapy elderly Hazard assessment Hepatitis Hepatitis C Hepatocellular carcinoma Human health and pathology Humans Hépatology and Gastroenterology Life Sciences Liver cancer Liver Neoplasms - drug therapy Older people Patients Pharmaceutical sciences Pharmacology Ramucirumab Regression analysis Safety Sorafenib sorafenib intolerance Subgroups Survival Treatment Outcome VEGFR2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background & Aims Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH‐2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha‐fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post‐hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (
ISSN:	1478-3223 1478-3231
DOI:	10.1111/liv.14462